A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Completed · Phase 3

Conditions studied: Hypertension

In brief

The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertension

Key facts

Study ID

NCT00200434

Run by

Mylan Bertek Pharmaceuticals

People needed

600

Starts

2002-10-01

Expected to finish

2003-10-01

Last updated by the study team

2005-09-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Average sitting diastolic blood pressure (DBP) greater then or equal to 90 mmHg and less then or equal to 109 mmHg at screening and baseline, in patients on background antihypertensive therapy taking at least one and no more than two of either ACE inhibitor, ARB, or diuretic.

You may not qualify if…

• Recent myocardial infarction or stroke
• Contraindications to beta-blocker therapy

Where it is running

• Mylan Pharmaceuticals Inc. — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.